Novartis AG

Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. (2020) De Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, et al. Journal article Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study (2020) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study (2020) Reich K, Koerber A, Mrowietz U, Sticherling M, Sieder C, Frueh J, Bachhuber T Journal article Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: Results from a claims database analysis (2020) Rech J, Sticherling M, Stoessel D, Biermann MH, Häberle BM, Reinhardt M Journal article Correction to: Mode of action-based risk assessment of genotoxic carcinogens (Archives of Toxicology, (2020), 94, 6, (1787-1877), 10.1007/s00204-020-02733-2) (2020) Hartwig A, Arand M, Epe B, Guth S, Jahnke G, Lampen A, Martus HJ, et al. Journal article, Erratum Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors (2020) Pinter A, Kokolakis G, Rech J, Biermann MH, Häberle BM, Multmeier J, Reinhardt M Journal article Measurement of Skeletal Muscle Fiber Contractility with High-Speed Traction Microscopy (2020) Rausch M, Böhringer D, Steinmann M, Schubert DW, Schrüfer S, Mark C, Fabry B Journal article Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies (2019) Coates LC, Wallman JK, McGonagle D, Schett G, McInnes IB, Mease PJ, Rasouliyan L, et al. Journal article Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis (2019) Rech J, Sticherling M, Biermann M, Haeberle B, Reinhardt M Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution